Coherus Biosciences price target lowered to $13 from $15 at Barclays

Barclays analyst Balaji Prasad lowered the firm’s price target on Coherus Biosciences to $13 from $15 and keeps an Overweight rating on the shares post the Q4 results. Udenyca declined as expected, with an auto-injector launch being the new element, the analyst tells investors in a research note. The firm sees the stock as undervalued, but notse that on-time launches and initial traction are critical.